Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | COCCn1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(8.78,-4.52,;9.56,-5.85,;11.1,-5.84,;11.87,-7.17,;13.41,-7.16,;14.32,-5.91,;15.79,-6.38,;17.12,-5.61,;18.45,-6.37,;19.79,-5.6,;18.46,-7.92,;19.8,-8.69,;21.13,-7.92,;17.13,-8.7,;17.12,-10.24,;15.79,-11,;15.78,-12.53,;17.11,-13.31,;17.11,-14.85,;18.45,-12.54,;18.45,-11,;19.79,-10.23,;15.8,-7.93,;14.33,-8.41,;13.86,-9.88,)| |